Ticker League

EBITDA for SELLAS Life Sciences Group (SLS)

Latest filings through · Reported

Metric

TTM

−$22.37M

YoY change

-4350.5%

5Y CAGR

—

Peak year (2013)

$7.63M

EBITDA history chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025

Latest: −$26.86M

EBITDA growth chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025

Latest: -4350.5%

EBITDA history table for SELLAS Life Sciences Group (SLS) from 2006 to 2025

  • 2025−$26.86M-4350.5%
  • 2024$632.00K+19.5%
  • 2023$529.00K-101.7%
  • 2022−$31.49M+71.9%
  • 2021−$18.32M+11.7%
  • 2020−$16.40M—
  • 2019$0.00—
  • 2018$0.00-100.0%
  • 2017−$23.04M+44.1%
  • 2016−$15.98M-57.3%
  • 2015−$37.48M+2.4%
  • 2014−$36.61M-579.9%
  • 2013$7.63M-122.2%
  • 2012−$34.38M+203.6%
  • 2011−$11.32M-4.2%
  • 2010−$11.82M-35.1%
  • 2009−$18.22M+27.9%
  • 2008−$14.24M+30.3%
  • 2007−$10.93M+354.4%
  • 2006−$2.40M—

EBITDA values are taken from SELLAS Life Sciences Group's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at SELLAS Life Sciences Group (SLS)

According to SELLAS Life Sciences Group's latest reported financial statements, the company's current EBITDA (TTM) is −$22.37M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

The 2025 reading of SELLAS Life Sciences Group (SLS) EBITDA is −$26.86M – plunged 4350.5% year-over-year.

Between 2013 and 2025, SELLAS Life Sciences Group EBITDA plunged 452.2%, falling from $7.63M to −$26.86M.

$7.63M stands as the all-time-high annual EBITDA, posted in 2013, against a low of −$37.48M during 2015.

SELLAS Life Sciences Group EBITDA by Year

SELLAS Life Sciences Group EBITDA 2025: −$26.86M

SELLAS Life Sciences Group EBITDA in 2025 was −$26.86M, plunged 4350.5% below 2024.

SELLAS Life Sciences Group EBITDA 2024: $632.00K

2024's EBITDA for SELLAS Life Sciences Group came in at $632.00K, grew 19.5% from 2023.

SELLAS Life Sciences Group EBITDA 2023: $529.00K

SELLAS Life Sciences Group posted EBITDA of $529.00K in 2023, plunged 101.7% below 2022.

SELLAS Life Sciences Group EBITDA 2022: −$31.49M

In 2022, SELLAS Life Sciences Group reported EBITDA of −$31.49M, surged 71.9% from 2021.

SELLAS Life Sciences Group EBITDA 2021: −$18.32M

SELLAS Life Sciences Group EBITDA in 2021 was −$18.32M.

See more financial history for SELLAS Life Sciences Group (SLS).

Sector peers by EBITDA

Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by their latest EBITDA

Frequently asked questions

SELLAS Life Sciences Group (SLS) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview
Capital Return

No dividends paid by this company.